5,300 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,300 shares of the medical equipment provider’s stock, valued at approximately $560,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter worth $25,000. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Brooklyn Investment Group acquired a new position in Zimmer Biomet in the third quarter valued at about $35,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management acquired a new position in Zimmer Biomet in the fourth quarter valued at about $40,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ZBH shares. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

NYSE ZBH opened at $112.91 on Thursday. The company has a market cap of $22.48 billion, a PE ratio of 25.37, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm’s 50-day simple moving average is $106.41 and its two-hundred day simple moving average is $106.93.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the firm earned $2.20 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.